Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence AUSTIN, ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

Blood cancer treatment is entering a new era, bringing powerful breakthroughs that offer renewed hope to people living with leukemia, lymphoma, myeloma, and other blood cancers. Cutting-edge targeted ...

A potential first-ever FDA-approved treatment for smoldering myeloma received a positive review from an advisory committee, but not without reservations, even from panelists who voted in favor. By a 6 ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Lenalidomide is an oral immunomodulatory agent widely used in the treatment of multiple myeloma, mantle cell lymphoma, and non-Hodgkins Lymphoma. The launch of Accord's Lenalidomide Capsules provides ...

September is Leukemia and Lymphoma Awareness Month. An estimated 1,629,474 people in the United States (US) are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes ...

DelveInsight's BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...